Seres Therapeutics, Inc. Cash and Restricted Cash
Seres Therapeutics, Inc. (MCRB) had Cash and Restricted Cash of $17.84 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $17.84M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $38.50M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $54.43M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $56.31M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $17.84M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $38.50M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $54.43M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $56.31M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $54.05M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $67.52M 10-Q · filed 2026-05-05 | |
| 2024-12-31 | $39.46M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $76.70M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $81.11M 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $119.61M 10-Q · filed 2025-05-07 | |
| 2023-12-31 | $136.15M 10-K · filed 2026-03-12 | |
| 2023-09-30 | $178.10M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $237.71M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $103.03M 10-Q · filed 2024-05-08 | |
| 2022-12-31 | $171.22M 10-K · filed 2026-03-12 | |
| 2022-09-30 | $213.58M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $135.01M 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $161.38M 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $188.00M 10-K · filed 2025-03-13 | |
| 2021-09-30 | $227.46M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $74.00M 10-Q · filed 2022-08-03 | |
| 2021-03-31 | $66.58M 10-Q · filed 2022-05-04 | |
| 2020-12-31 | $116.05M 10-K · filed 2024-03-05 | |
| 2020-09-30 | $207.33M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $61.54M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $54.86M 10-Q · filed 2021-05-04 | |
| 2019-12-31 | $65.13M 10-K · filed 2023-03-07 | |
| 2019-09-30 | $49.41M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $102.34M 10-Q · filed 2020-07-28 | |
| 2019-03-31 | $53.71M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $85.93M 10-K · filed 2022-03-01 | |
| 2018-09-30 | $57.23M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $59.47M 10-Q · filed 2019-08-06 | |
| 2018-03-31 | $48.71M 10-Q · filed 2019-05-02 | |
| 2017-12-31 | $36.20M 10-K · filed 2021-03-02 | $37.60M 10-Q · filed 2018-05-09 |
| 2017-09-30 | $47.54M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $35.16M 10-Q · filed 2018-08-02 | |
| 2017-03-31 | $43.30M 10-Q · filed 2018-05-09 | |
| 2016-12-31 | $55.94M 10-K · filed 2020-03-02 | |
| 2015-12-31 | $75.47M 10-K · filed 2019-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |